<DOC>
	<DOCNO>NCT01242228</DOCNO>
	<brief_summary>This study evaluate long-term safety efficacy concomitant administration ASP1941 DPP-4 inhibitor Japanese patient type 2 diabetes mellitus .</brief_summary>
	<brief_title>A Study Assess Safety Efficacy ASP1941 Combination With Dipeptidyl Peptidase-4 ( DPP-4 ) Inhibitor Type 2 Diabetic Patients</brief_title>
	<detailed_description>This 52-week multi-center , open-label , non-comparative study subject type 2 diabetes mellitus inadequate glycemic control DPP-4 inhibitor alone . Dosage may increase treatment period subject fulfill increase criterion investigator adjudicate impact subject safety .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Dipeptidyl-Peptidase IV Inhibitors</mesh_term>
	<criteria>Type 2 diabetic patient receive DPP4 inhibitor monotherapy least 4 week HbA1c value 6.5 9.5 % Body Mass Index ( BMI ) 20.0 45.0 kg/m2 Type 1 diabetes mellitus patient Serum creatinine &gt; upper limit normal Proteinuria ( albumin/creatinine ratio &gt; 300mg/g ) Dysuria and/or urinary tract infection , genital infection Significant renal , hepatic cardiovascular disease Severe gastrointestinal disease</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>ASP1941</keyword>
	<keyword>Diabetes mellitus</keyword>
	<keyword>Dipeptidyl peptidase-4 inhibitor</keyword>
	<keyword>DPP-4 inhibitor</keyword>
	<keyword>long-term safety</keyword>
</DOC>